CHEK2 mutation-associated breast tumors are more likely to be estrogen receptor (ER)-positive than sporadic breast cancers, and patients with breast cancer who carry a CHEK2 mutation respond well to tamoxifen [51,52,53,54]. Here, ESR1 is linked to breast carcinoma.